Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Bonesupport, Audiocast with teleconference, Q1'24

By Inderes4/25/2024, 8:00 AM
Bonesupport

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Emil Billbäck
00:02 - 16:52

Thank you very much, operator, and good morning and welcome everyone to BONESUPPORT's quarter one 2024 results call. My name is Emil Billbäck. I'm the CEO of BONESUPPORT. And sitting next to me is Håkan Johansson, our CFO. So we will use the next roughly 25 minutes to guide you through the presentation of the first quarter results. And then we'll open up the line for questions and answers. So next slide please. So before starting this presentation, I would like to draw your attention to the disclaimers that might be covering any forward-looking statements that we will make today. Let's move forward. So I would like to begin the presentation by drawing your attention to some of the highlights that we have displayed in the report released this morning. So overall quarter one sales were at 184 million, which corresponds to a reported growth of 54% year over year. In constant exchange rate, the growth rate was as well 54%. The operating result for incentive provision was 42,000,006, which is a profit improvement versus the same period last year of 37 million Swedish krona. The reported EBIT was 32 million Swedish krona, marking our fifth quarter as a profitable company. The main highlight in the period has been the continued strong market penetration of CERAMENT in the US. Sales reached 93 million Swedish krona, and we see a good momentum in the business within most of our geographies and indications. The market dynamics are positive and at a growth rate of more than ten times market growth, we are taking large chunks of market share. There were two important U.S. regulatory milestone achievements in the quarter. We received FDA market authorization for CERAMENT G. For open fracture trauma, and we received FDA market authorization for CERAMENT BVF for Spine Inter Body Fusion. These market authorizations are enabling the future execution of our strategy. And I will come back to the possibilities we see with the CERAMENT platform. But first let's look at the sales development on the next slide. So you're probably familiar with this chart. It shows the last 12 months sales in Swedish currency every quarter since quarter one, 2017, in stacked bars per region and per product category, the top line is advancing with a solid and steep trajectory. It is mainly the antibiotic eluting segment, which is driving the development with 103% growth in quarter one, 2024 versus quarter one 2023. CERAMENT G has been in the US market for about six quarters, and there is some kind of legislation on DVF, but I anticipate much less than anyone expected. We have come out of the pandemic with full speed, and we see strong progress in both geographies. Segments with an almost linear development since quarter one 2022. So I will offer one more slide on this theme, actually, where we can see this a bit clearly, where we have looked at sales per quarter in constant currency. So if you go to the next slide, what you see here is that in the most recent quarter, quarter one 2024, with sales of 184 million Swedish krona, we can conclude that in constant currency, sales have tripled over the last eight quarters, and they have doubled in the last five. There was already a very strong trend in the business even before Q1 2024. It was launched in the US. But from quarter 4 in 2022, that trend has really moved up a notch. We also see a rather steady and solid market penetration, which is common for unique and successful orthopedic products such as CERAMENT, where the promotion is preceded by necessary hospital system approvals and the winning over of surgeons takes place surgeon by surgeon rather than in big chunks. Let's go into the details for North America on the next slide. So, with sales of 141 million SEK in the quarter, it corresponds to a reported growth of 65% year over year and the same number there also in constant exchange rates. One of the highlights of the quarter was, of course, the strong sales of CERAMENT G. In Q1 2024, we saw really strong uptake and sales reaching 93 million, which is up 17 million or 22% sequentially. The strong continuous pace of hospital approvals has remained the same as in previous quarters. However, the overall priority of our sales teams right now lies in the training and education of newly recruited surgeons at hospitals where contracts have been secured. The other highlight is, of course, the market authorizations for CERAMENT. CERAMENT and Gentamicin. And I thought I'd go through that a bit more in detail on the coming slide. So, if we start on the next slide with the Spine Inter Body Fusion authorization, I think most of you are aware that the main reason for fusion surgery of the spine is to stabilize the spinal column and reduce pain caused by certain spinal conditions. And the fusion surgery involves joining two or more vertebrae together to create a solid bony bridge with the purpose of eliminating motion between the fused vertebrae. Inter Body Fusion (IBF) is the procedure where a damaged disc is replaced with a cage, which is then filled with organic bone graft or a bone graft substitute, and then accomplishes the fusion. The posterolateral fusion involves fusion of the transverse processes in proximity to screws, rods, and potential plates. As I think it's clear from the picture. So we've already had regulatory clearance for posterolateral fusion. And since March of this year, CERAMENT BVF is now also approved for Inter Body Fusion. This means that we're allowed to fully enter the spinal fusion segment in the US, adding about 750,000 procedures to the addressable market. And this is a market where one out of five spinal procedures fail to fuse, and 40% of the procedures are made with off-label use of local antibiotics. So we will enter this market segment with a strong value proposition. So CERAMENT is an Ortho Biologics platform for bone healing where local substance delivery can be utilized. And it is the solid evidence behind CERAMENT's strong bone remodeling capabilities that has facilitated the fast IBF approval. In preparing for entering the market. Our focus lies on building pre-clinical application data, collecting and analyzing the necessary observations, and building training programs for surgeons. We will also work methodically to ensure the right skills and the right resources within a distributor-led sales force, as well as building a strong network of key opinion leaders. All in all, these important activities mean that we will enter the market in quarter four of 2025 at the earliest. We are thorough in our preparations, and we know what it takes to make and achieve solid market penetration and market launch. But let's also turn to the next slide and look at the open fracture trauma approval. So in regards to open fracture trauma, we wanted to be clear that CERAMENT G has received broad and wide approval. That means that all extremities are included on the label. The only limitations given are that CERAMENT G volumes should not exceed ten milliliters. And we have also on the labeling the wording that the Gustilo-Anderson IIIB fractures are not supported by clinical evidence for CERAMENT G; the Anderson IIIB open fractures are only about 8% of the total number of procedures in open fracture trauma. So, only a very small part. In the data submitted to the FDA, close to 500 patients were demographically matched and compared, and a total cohort of 3060 patients were used to build a definition of standard of care. The patient outcome in the evidence submitted is very impressive. In the summary letter, the FDA wrote that the infection rate for CERAMENT G in the treatment group is extremely low. And that bone remodeling at 96% is favorable to standard of care. As a consequence of the low infection rate and the high union rate. The amputation rate in the extensive study materials submitted to the FDA for the treatment group was only 3.7%. Now, this can be compared to the reference material for amputation rate. Historically, for these kinds of injuries, it is at 16%. So, we're currently working to ensure that the more than 100 hospital systems where CERAMENT is approved already for bone infections also get a registration for CERAMENT G on open fracture trauma. We're already seeing some surgeons requesting the use of CERAMENT G for open fracture trauma. But we should keep in mind that it will take a few months before all the system updates and registrations are done. And only after that will we see a tangible uptake within this indication. We are also assessing the merits to file for an NDA for CERAMENT G in Open Fracture Trauma. The deadline for this is October 1st this year. And finally, I will say with the two recent market authorizations, I believe that CERAMENT really establishes its role as an Ortho Biologics platform with broad applications in various indications requiring bone healing. So if we go to the next slide and just do a quick refresher on the US market. We have earlier concluded, and this is from the Capital Markets Day data in 2022, that there are about 380,000 procedures a year in the US where bone grafts are used to enable healing. And the most common reason, the most common methodology for these surgeries and procedures is open fracture trauma. As you can see on the pie chart to the left, with the most recent regulatory clearance, another 132,000 procedures will be on label for CERAMENT G in open fracture trauma. And here I deduct the 8% which are the Gustilo-Anderson IIIB; our estimate, though, if you look at the total open fracture trauma procedures, is that off-label antibiotics are used in about 40% of the cases. And all of that, as I said before, is off-label. Now let's also turn to Europe before we hand over to Håkan and the financial part. So for the quarter, we saw sales of 43 million Swedish krona, which corresponds to a growth of 27% year over year, and that is 24% in constant currency. We see strong market dynamics in most of the European countries as there is a continued catch-up of the surgical backlog. Our strong development is also a reflection of significant market share gains. The antibiotic-eluting segment, which is segment G and V combined, grew by 28% in the quarter versus last year. Now, much of the focus in this report, admittedly, has been on the US given the recent approvals, but I want to underscore that we've seen strong progress in Europe as well, with hybrid markets, which are Spain and Italy, performing especially well. To achieve this, we have continuously ramped up tactical initiatives. Participating in conferences and arranging symposia. There is a high interest in the product and there is high interest in the different application techniques. In total, over 400 orthopedic surgeons attended our symposia held at the key conferences in the US and Europe. These symposia were facilitated by faculty members who are distinguished orthopedic surgeons and featured a blend of clinical evidence, presentations, patient cases, and panel discussions. Also, to meet the evolving and increasing demand in Europe, we have recruited additional resources within medical education and event execution, and some of those additional headcounts you will see reflected also in the financial part and the costs that we will now present. So over to you, Håkan. For a more detailed view on the numbers. Thank you, Emil. So, net sales improved from 119.7 to 184.4 million, equaling a growth of 54%, with the same 54% in constant exchange rates. Emil has already spoken about strong performance in the two segments and the major drivers behind the sales acceleration. So let us move to the next slide. The contribution from the North America segment.

Håkan Johansson
16:52 - 21:40

Improved by 30.9 million and amounted to 55.8 million. The improved contribution relates to the increased sales after the effect from increased costs. Sales and marketing expenses during the quarter amounted to 78.4 million, compared with 55.7 million the previous year, of which sales commission to distributors and fees amounted to 47.8 million, compared with 29.5 million the same period last year. The increase of 4.4 million, excluding sales commissions and fees, was mainly driven by the organizational investments made following the launch of CERAMENT G and the underlying sales growth. From the lower graph showing net sales as bars and gross margin as the orange marker. It can be noted that the gross margin continues to strengthen, reported at 95.3%. In Europe and the rest of the world. A contribution of 10.7 million was reported, compared with 7.3 million the previous year. Sales and marketing expenses increased by 5.4 million and were driven by field vacancies, an increase in sales representatives, and a high level of market activities to capture the momentum we now see in Europe, but also by one-off expenses of 1.1 million. From the lower graph and the orange marker, you can see the gross margin remaining stable with a minor impact from product and market mix. So let's go to the next slide, please. Selling expenses in the euro increased to 5.4 million versus last year, of which 1.1 million relates to one-time expenses and 0.4 million to currency effects. In Europe, we have vacancies and increased our total Euro commercial organization by five heads compared to the previous year. The sales cost increase in North America in the quarter related to organizational investments, ramp-up in activity level of congresses, medical education, and of course, the continued launch of CERAMENT in the U.S. If we look at R&D as presented at our Capital Markets Day in November, we're indeed focused on execution of strategic initiatives such as spinal fusion and the planned FDA market authorization submission for CERAMENT V in the US. These initiatives have been in a preparatory and design phase during the quarter, with increasing expenses estimated for the coming quarters. And finally, covering administration. Underlying administration expenses, excluding effects from the long-term incentive programs, remain on a stable level. So let's move to the next slide, please. The adjusted operating profit was reported to be 4.1 million, compared with 4.6 million for the same period the previous year. An improvement of 3.7 million following a strong sales performance and further supported by a favorable impact from currencies of 6.8 million. The difference between adjusted EBIT and reported EBIT operating results are provisions regarding long-term incentive programs, amounting to an expense of 9.3 million this year, compared with 3.8 million the previous year. As you could see on the previous slide, the share saving program approved by the AGM in May of last year, with vesting starting at the 1st of January this year, represents the higher share of the expense, but 3.8 million relates to the programs ended in 2023 and following the share price depreciation from year-end 2023 to end, the allotment of shares was executed and social charges were paid. Of the total cost of 9.3 million in the period, only 0.3 million is cash flow impacting. A positive cash flow from operations was reported at 17 million, despite the continued unplanned build-up of both semi-finished and finished products, ensuring full flexibility to future market needs, but also including preparation to launch the third generation segment D in the US in the second quarter this year. The third generation was launched in Europe during last year, involving both increased ease of use and reduced environmental impact. And with this, I hand it over back to you. Emil.

Emil Billbäck
21:42 - 23:02

Thank you, Orkun. So let's wrap up this quarter one presentation. Both of us are, of course, together with the entire organization, very pleased with the performance that we have seen in the quarter, as well as the continuous trend that the entire business is moving at. The strong growth is mainly attributable to the continued successful launch of CERAMENT G in the US, but we're also growing steadily in Europe, adding CERAMENT users in all geographies. Apart from the strong financial performance, the highlight of the quarter is the settlement through the two FDA market authorizations, proving its role as an Ortho Biologics platform with broad applications in various indications requiring bone healing. Thanks to clinical superiority to standard of care, CERAMENT is constantly increasing its user base and enabling surgeons to drive towards a better patient outcome. We feel strong confidence in the market guidance given to grow sales in 2024 by more than 40%. I thank you for your attention and with this, we conclude our call and open up for questions.

Matthias Watson
23:06 - 23:29

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Mathias Waddesdon from SEB. Please go ahead.

Emil Billbäck
23:31 - 23:32

Hi there.

Unknown
23:32 - 24:12

Thanks for taking my questions today. First one, to start where you ended the email with above 40% sales growth, target organic. When you set forth this target at the 2023 CMD. Did you have in mind back then the open fractures with CERAMENT G. That it was approved so fast then you know, the reimbursement codes will be in place I guess around September for fractures. And I understand, or my guess is, at least, a boost in sales towards the end of the year. So yeah, just maybe talk a little bit about that to start with.

Emil Billbäck
24:14 - 26:21

Yeah. Thank you. Yes. And good morning to you. When we defined the guidance at the Capital Markets Day, we concluded that there are so many moving parts, there are so many opportunities, and there are so many pending both regulatory authorizations and initiatives, that we will only give guidance for one year at a time currently. So that's when we said above or over 40% growth. At that time, I could not have anticipated that the open fracture trauma authorization would have come so fast. As a matter of fact, I've been asked before, and the above 40% or more than 40% growth was a definition of guidance that was given, even excluding open fracture trauma. So you could almost say that comes on top. Then the open fracture trauma indication has immediate reimbursement coverage in the US as when the patient comes in, the injury is categorized on a DRG coding system, and then the surgeon is basically free to more or less use products of their liking to heal and take care of the patient. But what we will apply for before October 1st, if our analysis points in that direction, is to get an NTAP with CMS. We did that before for bone infection, which was granted. And we're going to do now the same if it's granted also for open fracture trauma. I want to remind everyone that it's specifically only for the CMS patients in the Medicare program. And it would then be, if granted, an incremental reimbursement above what is given in the regular DRG. Good.

Unknown
26:21 - 26:49

Now we covered the next one as well, but maybe another one, you know, further new interesting data showing here later in the year with CERAMENT. Question here, to what extent, would the CERAMENT dataset be crucial for you? We obviously always try to triangulate how important all study results are for the commercial success. So of course your thinking here is much appreciated as well.

Emil Billbäck
26:50 - 28:52

Yeah, yeah. Thank you. Yes, I think we all learned that in orthopedics breakthrough devices like this, which is pioneering the market. There's not this huge volatility in sales, but rather win surgeon by surgeon, contract by contract, hospital by hospital. Now back to CERAMENT. CERAMENT, if it comes out. Positively for sentiment would, of course, be a formidable tool for us on this journey going forward, both to drive even faster the conversion from an outdated standard of care where there's already plenty of study showing superiority for CERAMENT with antibiotics, and CERAMENT would then be a major milestone in actually proving that local antibiotics distributed in a synthetic bone graft to ensure bone healing is indeed a favorable option versus the more antiquated treatment methods. But the other thing is also that such study results would help us in our discussions regarding the value of the product and the health economic benefits too. I think everyone knows that systemic antibiotics is one of the biggest reasons for antibiotic resistance. And there is clearly a health economic effect also of keeping the patient longer in hospitals and enduring more infections and more complications. So there's a lot of dimensions on a positive CERAMENT study that could help us to even further accelerate the journey in the future. That's a.

Unknown
28:52 - 29:09

Clear as ever. Then my last question may be, you know, about good cash flows once again. And cash position, of course, rising. I appreciate this is probably a long answer, but maybe if you could share a few words on sort of capital allocation going forward. That's my last one. And then I jump back to the queue.

Håkan Johansson
29:12 - 29:48

Again, I think that it's good to see that somehow the operational leverage is also supporting the cash flow and, as previously communicated, is more short-term. And it gives us the assurance to have the necessary funds also for the investment initiatives and the initiatives that we have revealed and presented at the Capital Markets Day. So, short-term, that's where we have the focus and how to use the cash flow that is now generated by the business.

Emil Billbäck
29:49 - 30:18

Yes, I think also it's, to Hakan's point here. It makes us very resistant to variability in the business. It gives us the freedom to fully realize those strategic plans that we have communicated at the Capital Markets Day. So on one hand, you can say, yeah, we're out of the tunnel and the open land is ahead of us now. Good. Thank you. Thank you. Mathias.

Matthias Watson
30:21 - 30:27

The next question comes from Eric Castle from Danske Bank. Please go ahead.

Unknown
30:28 - 30:37

Hi. Good morning. Good morning. First, just sort of a housekeeping question. I was wondering what the one-off expense of 1.5 million in Europe relates to.

Håkan Johansson
30:38 - 30:57

So, it's primarily. The biggest part is, for the first time, what I don't want to overlook. We had to do provisions for debts in the Euro segment, and that's the biggest part of that amount.

Unknown
30:59 - 31:19

Okay. Got it. Thank you. And then, since you're talking about having your sales catering more to existing users, can you tell us anything about the effects that's having on getting surgeons to use it more? Can you say or maybe quantify anything about what you've seen in the past year in same surgeon sales growth, on average.

Emil Billbäck
31:22 - 32:57

Okay. Good morning, Eric. So the line broke up a little bit. I think I heard a question, but if I'm off the mark, please correct me and repeat yourself. So, the hospital system approvals last year took off really fast. I mean, faster than the group here had anticipated. And when we receive the hospital system approval, we find it also important to quickly reach out to potential future users to get out to the hospitals, to get out to the surgeons, because it's an invitation by at least the surgeons that have been part of the user committee and the medical advisory committee, that they get further information about the product. So, I can say that with such a high level of hospital system approvals. We have been very focused on getting to those big clinics, the big users, the prominent orthopedic surgeons. And over the last, I would say 8 to 9 weeks, we have had a record pace of new users of CERAMENT G. And I don't think that's controversial in any way, because if you get a lot of hospital system approvals, that also encourages and opens the door to promote the product, and we know that when we can promote the product.

Unknown
32:58 - 32:59

In daily

Emil Billbäck
32:59 - 33:10

Use, we have a strong conversion from the more antiquated standard of care or the previous usage that the doctors have used before.

Unknown
33:14 - 33:34

Okay. Thank you. Thank you. Um, then next question. I mean, I hope you hear me all right, just say if you don't, but high rates of cannibalization in the US, I mean, of CERAMENT, that is I mean, it's some of it's being lost to other alternatives. See other synthetic grafts or does it all relate to switching over to CERAMENT?

Emil Billbäck
33:37 - 35:31

Yeah. You see, I don't think the cannibalization. I think it's rather modest. Um, it's I think it's less than Lee, but also a lot of the analysts would have anticipated. So if you look in the numbers, the sales of CERAMENT segment, CERAMENT in the quarter, I think was down some, some 7%, uh, which is quite trivial, I think given the, the pace of CERAMENT G. But there's one more thing we have to take into consideration here before. We had recruited almost 400 sales reps, and the only product they had from us was CERAMENT, and that got full attention from the salespeople when they also were selling their metal products and their processes and others. And now with CERAMENT G, of course, all focus is on CERAMENT G. So the cannibalization mainly takes place in the time allocation of the salespeople, and I think not so much in the sales yet, but the few percentage point that the reduction has been in, in CERAMENT is probably the similar pattern that we've seen in Europe that when the doctor has CERAMENT available with antibiotics, they can get the same great bone remodeling capabilities and they can also get protection. And now also the latest approval prevention from infection, they start using that more and more as a first line therapy, even if the infection incidence might be low. Um, we don't see that we've lost customers. Uh, the surgeons stay within the family, so to say.

Unknown
35:34 - 35:54

Okay, but we still have CERAMENT down 9% year over year in the US. And if there is no real cannibalization and just maybe the effect of sales not focusing on it, should we just expect CERAMENT to sort of fade away? I believe the previous answer, when that it was supposed to be more like the more stable, so to say. Has that changed?

Emil Billbäck
35:56 - 36:59

Yeah, clearly there are accounts that have used CERAMENT and they now have switched to CERAMENT G or another account. I mean, specific surgeons, of course. Um, absolutely. I don't think it will fade away. I think we can look at the European sales and, we see that CERAMENT as a pure bone remodeling, treatment has its place, especially for well-planned surgeries, elective surgeries with very low risk of infection. There will be surgeons that will then select CERAMENT to favor the slightly lower price of the product. For where CERAMENT and Simon will park itself, I think is for the future. It's, uh, difficult for speculating that right now.

Unknown
37:00 - 37:30

Okay. Thank you. Um, I'll just squeeze in one last one. Um, and that's on the three. See, I mean, we do see a lot of PMMA use and other antibiotic bone grafts in the US. Um, and you choose to not really account for it in your, say, market size. I'm just wondering, why wouldn't surgeons just use that off-label, um, when they are using sort of alternative products as of now? So it's very good.

Emil Billbäck
37:30 - 37:37

And there's I have to apologize. There's so much noise on the line that I couldn't I couldn't hear the first part of the question.

Unknown
37:38 - 38:02

I'm sorry, I'm having a bit of issues with my headset. Um, I'll try again. Um, when it comes to just, you know, we see there's a lot of PMMA being used and other antibiotics, including bone graft. Um, why wouldn't just surgeons use, uh, sort of labeling that? Because you've decided not to really include that indication, um, in your market sizing. So just curious on that part.

Emil Billbäck
38:06 - 38:06

Did you hear the question?

Håkan Johansson
38:07 - 38:07

Unfortunately.

Emil Billbäck
38:08 - 38:12

We have to. We have to both apologize because we cannot hear the question.

Unknown
38:13 - 38:19

I'm sorry. It's like a boiler room in here today with all the reports. I'll jump back into you and see if I can try again later.

Emil Billbäck
38:19 - 38:21

Maybe you can type the question. Eric.

Unknown
38:24 - 38:29

Yeah. I'll jump back in here instead.

Emil Billbäck
38:31 - 38:46

Thank you. Okay, maybe if you type the question, we'll do our best to respond to it. Well, that was a little bit difficult to hear. Do we have any further questions from any other participants?

Unknown
38:48 - 38:52

Yeah, Christopher is here. Said my line was unmuted. Do you hear me?

Matthias Watson
38:53 - 38:59

The next question comes from Christopher Burge from Carnegie Investment Bank AB. Please go ahead.

Emil Billbäck
39:01 - 39:01

There you are.

Unknown
39:02 - 39:03

Hi. Can you hear me now?

Emil Billbäck
39:04 - 39:05

We hear you perfectly.

Unknown
39:06 - 39:38

All right. Good morning. Uh, three topics I would like to ask you about. Uh, first one is, uh. Uh, if I remember correctly, I think you said last quarter that there were a record number of hospital approvals last year, and that was something that could accelerate sales growth, maybe late spring, early summer. Is this something you have seen already, or do you still expect this to happen here, maybe late Q2 into the third quarter?

Emil Billbäck
39:39 - 40:35

Yeah, we had at the end of the year we had a really good success rate with hospital system approvals. And as soon as they were, as soon as they landed, as soon as we had a signature on paper, the sales team went off with a clear prioritization list and focus list. And indeed, I can confirm that those hospital system approvals have also resulted in a high surge in conversion rate. So they take place sequentially. First, we need the hospital system approval, and then we can go out into those hospitals that are associated with the contract and promote it. And, uh, I mentioned before that for the last 8 to 9 weeks, we've also seen a good pickup in new users, new surgeons, and new clinics.

Unknown
40:38 - 41:06

Okay. Great. Thanks. And then on the trauma indication, how do you expect that to impact sales in the coming quarters. You talked about the hospital approvals. Of course. Uh, wondering whether you have noticed the surgeons hospitals being more price sensitive for this indication than for bone infection. And, uh, I don't know if. Is it too early to say anything about hospital approvals for this indication? Uh, isolated?

Emil Billbäck
41:08 - 42:12

Yeah. Um, I haven't noticed. We have not noticed any higher price sensitivity, actually. Uh, maybe that's because it's so new. And those surgeons that immediately picked up the phone are the ones very hungry and eager to try the treatment. And so far, we only have a handful of hospital systems where we have been able to change the administration codes and get open fracture trauma on the listing. So I think it's, uh, it's more likely as, as you also concluded, Christopher, that by after summer. So maybe we come to early September, that's when we should be through with the big hospital system approvals. And that means also we will intensify our marketing efforts. When that is done, there are a couple of big congresses in the autumn focused on trauma, which we target to get out with the message.

Unknown
42:14 - 42:14

Um.

Emil Billbäck
42:15 - 42:17

Did I cover your full question?

Unknown
42:18 - 42:41

Absolutely. And what do you think? If we look at the initial launch for bone infection and the sales you had the first quarter. Do you think it's fair to see, you know, similar effect on sales, on top of current sales and the top of current sales trend for trauma? Or is that too optimistic a scenario?

Emil Billbäck
42:45 - 43:53

Yes, it's. I couldn't give such guidance. Christopher. Where I sit now or with the data we have, what I want you all to remember, though, is we received the market authorization from the FDA in May. 2022. And because we knew the work that had to be done with the hospital systems, we told everyone that we would launch in October. And then the launch came five months later. So it's the same here. I mean, it takes five months, basically, to really get on the system and get everything up and running. And there are quite a few doctors also that would like to use the product, but they're not going to do it until they know that it's fully endorsed in the system because of them ending up in troubles otherwise. And then the uptake, I, I couldn't tell actually, I don't know myself. Of course we built different models, but I'm not ready to share that with the market. So I guess we will have to get our first observations and then probably be a little bit clearer in our guidance going forward, looking into 2025 and forward.

Unknown
43:54 - 43:55

Yeah, yeah. That's fine.

Unknown
43:56 - 44:25

Last question, maybe for, what can cost? If you could maybe talk a little bit about how you expect both selling expenses and R&D costs going up or moving up coming years or maybe, let's say. Is it possible to give sort of indication in absolute terms, how much higher selling expenses and R&D costs would be in 2026 versus 2024, a rough figure.

Håkan Johansson
44:27 - 45:08

Against Microsoft. It's very hard to. To give very clear guidance. I think that what you can expect and what you will see is that we will continue to make investments step by step, following some underlying set of growth and to continue to support sales growth. And we don't expect that to come in a big chunk. So it will be more somehow following the development. Which then also means that what you could expect is the selling expenses as a percentage of sales, but that should be possible to come down gradually.

Unknown
45:09 - 45:10

Yeah.

Unknown
45:10 - 45:23

On the R&D cost. I guess at some point you want to also file for FDA approval for spinal fusion. When do you. When should we assume?

Unknown
45:24 - 45:25

Costs for.

Unknown
45:25 - 45:30

Clinical trials related to that happened.

Emil Billbäck
45:32 - 45:46

So we will announce that at least one quarter in advance before that starts, that is not now. So it's for later to be making such an announcement.

Unknown
45:47 - 45:49

Okay. Thank you.

Unknown
45:50 - 45:51

Thank you, Christopher.

Matthias Watson
45:53 - 46:00

The next question comes from Sten Gustafsson from ABG Sundal Collier. Please go ahead.

Unknown
46:03 - 46:33

Good morning and thank you for taking my questions. I was wondering if you could share with us what type of market access you have today. When we look at the bone infection indication with 50,000 procedures annually in the U.S., what type of market access do you have today if you could potentially give some sort of indication there?

Emil Billbäck
46:36 - 48:05

So I mean, what we shared at the Capital Markets Day was a rough estimate on market shares. You ask for the market access, which then relates more, I think, to how many hospital system approvals we have so that we can get into the hospitals and start to promote the product. And in the very early days. Yeah, and in the early days of the launch, we also displayed how many hospital systems approvals we had. And then we stopped that reporting. We didn't do it because the numbers dropped, but we did it because they were taking off, actually. And we have more than 100 hospital system approvals. And, I mean, that roughly corresponds to between 1200 to 1500 hospitals. So that means we have good market access, slightly better than we anticipated. And we have an absolutely full schedule now with getting out to those hospitals where we have gotten approval and, possibly even that we will down prioritize getting more approvals because we are so busy meeting the expectations of those already granted approvals and get out to the clinics and explain what is this new product that has been put down in the system.

Unknown
48:08 - 48:23

Okay, so do I understand it correctly that you're roughly approved at 1200 to 1500 hospitals today? Out of is that like 5000 potential hospitals or.

Emil Billbäck
48:26 - 48:28

Yeah, it makes sense. Give or take. Yes.

Unknown
48:28 - 48:51

Yeah. Excellent. Thank you. My second question comes to the TPT approval you talked about in the previous quarter for outpatient care facilities. Have you noticed any interest from that group?

Unknown
48:52 - 48:54

Of facilities.

Emil Billbäck
48:55 - 50:47

Yes, thank you. The TPT was announced and came into effect on the 1st of January of this year and is valid for three years. The challenge with the US market, as always in everything we do, is that there's no central communication. There's no institution that sends out a note saying, 'Oh, look at this.' This has just been approved or this just has reimbursement. The most reliable source of information for healthcare practitioners on this topic is our sales resources. So, it's the same. We have to go out and constantly inform, sometimes 2 or 3 times before we really start to get traction. So what I can say is that in the first quarter of this year, there has been little, if any, impact from TPT. So, I think we should all anticipate that it will have more of a gradual ramp-up over the year and hopefully accelerate into 2025 as the coding gets more recognized, and as both the healthcare practitioners and the billing offices learn how to use this in a proper way for CERAMENT. It's very unusual for such a product to receive full TPT, so it also requires a bit of education. The healthcare providers do not want to make mistakes when it comes to a product that will incur expenses of close to $6,000. So, there's a bit of work actually behind all of these enablers before you really start seeing them pay tribute.

Unknown
50:49 - 51:07

Okay. Does this mean that you were approved at? I think you said that there were roughly 2000 facilities. All at once? Or do you also need individual approvals at each center or group of centers?

Emil Billbäck
51:07 - 51:46

It varies. I cannot give a solid answer on that because there are centers that require their own administrative approval. Some of the ambulatory care centers are linked and associated with hospitals or hospital chains. And sure, if the approval has been given there, then it's more or less automatic. But with such a generous and solid reimbursement, the approval for those that require it is usually very fast and quite simple because this TPT is lucrative.

Unknown
51:48 - 51:50

Excellent. Thank you very much.

Emil Billbäck
51:51 - 51:52

Thank you, sir.

Matthias Watson
51:54 - 51:59

The next question comes from Oscar Bergman from Redeye. Please go ahead.

Unknown
52:03 - 52:37

Hi, guys. Congratulations on a strong quarter. I only caught the tail end of the Q&A session, unfortunately, but I still have some questions. I know there's a lot of attention on you with sales, of course. So, naturally, we're seeing sales progressing very well there. But if we turn our attention to the EU market, can you just explain some challenges or opportunities that are there in the short term, for example, how is it going with the hybrid conversion and access to hospitals and so on?

Emil Billbäck
52:40 - 54:57

Yes. Thank you, Oscar. Absolutely. We always look forward to your questions. The traction in the hybrid market is very strong. It's going well, slightly above expectations. And here we have placed BONESUPPORT staff working together with either one distributor or several distributors covering part of the country. And this is like a miniature model of what we have in the US. So it gives us the opportunity to view and monitor metrics and follow up with the salespeople and really see that CERAMENT gets the proper market introduction. We can conclude that CERAMENT is not a product that fits all distributors without any handholding. It is a much more sophisticated product. It requires explanation. It's not generic. It's probably easier to sell a generic metal plate than it is to sell CERAMENT, which is a breakthrough biologic product. The challenge we see a bit in Europe is still the shortage of staff, which is holding back the acceleration of business, which is holding back further carving into the backlog of surgeries that built up during the pandemic. It has become a little bit better, mainly in the UK. There's also some relief in France, Italy, Spain, and Germany remains challenging. And the nursing staff shortage and also shortage of surgeons in general, which makes the total market development a bit slow. So the way we view this, of course, is when we're growing 27%, inevitably there are a lot of surgeons that are preferring CERAMENT instead of more traditional treatment modalities. So if you're growing that much faster than the market, you are taking market share. And for this, we are very proud of the team that they keep fighting, despite sometimes difficulties, to meet the right surgeons due to the staff shortage.

Unknown
54:59 - 55:25

And how would you compare the surgeons' standings on the hospitals in the US versus the EU market? I mean, in terms of new innovation coming in and the surgeons having something to say about that. For example, in the US, the surgeons have more of a say in what products they want to use for their procedures compared to the European market.

Unknown
55:26 - 55:26

Yes.

Emil Billbäck
55:26 - 56:30

The US is much more open to innovation. The biggest difference, probably, is that in the US, the clinician, meaning the person who really treats the patient, is much closer to the procurement office, is closer to the health economics of the clinic and the hospital in Europe, the clinician and the person looking at the cost of a treatment or the benefit of it are usually separated with a greater distance and different layers and hierarchy. So sometimes I wonder if certain European markets have tardiness as a strategy to avoid innovation. The whole conversation in Europe requires many more stakeholders before there is full acceptance, both of the clinical benefits and the health economic benefits. That process is shorter and more effective in the US, where they go more hand in hand.

Unknown
56:33 - 56:43

And how do you sort of overcome that obstacle in knowing that in an efficient manner? Or is it just something that you have to accept and then play along?

Unknown
56:45 - 56:46

Oh, we work hard.

Emil Billbäck
56:47 - 58:04

That's what we do. We work hard, and we have everyone in the organization with a tremendous passion also for changing the standard of care, because we have seen in clinical studies that we can reduce infections, we can reduce amputations. So that keeps us up at night sometimes. Uh, but for Europe, unfortunately, we are still a small player. We cannot anticipate that we will dramatically change the system or the modus operandi. So unfortunately, sometimes we are forced also to be patient and accept that the system in Europe is slower. But we do what we can, uh, with both continuing with clinical studies and doing health economic investigations, so that whenever there are different stakeholders that haven't understood the concept, we're ready with tailored material to answer those obstacles that different stakeholders might present in front of us. I think you see this with any medical device company that Europe is in general, uh, slower due to the more sclerotic administration and systems.

Unknown
58:06 - 58:06

Okay.

Unknown
58:06 - 58:26

Okay. Thank you. Um, I think we really only have one more question. And, um, I mean, you have said now a lot of hospitals in the US and in the EU. Um, are there any cases, any hospitals where CERAMENT has become sort of the standard of care at that hospital for those related procedures?

Emil Billbäck
58:28 - 59:16

Yeah, I think it's starting. It's of course, a great question. We, uh, we see especially in some of these university hospitals where they have done, um, structured and methodological evaluation of the product. And, uh, the results of that clinic have completely mirrored the strong results from the centrally produced studies, um, with the best in mind for the patient and for the, um, health economic impact. Several of these university hospitals have adopted uh, CERAMENT or V. As standard of care, uh, with bone infections, but also at an increasing pace with open trauma.

Unknown
59:17 - 59:25

Okay. And would you define that as well? 50% of all procedures carried out at a hospital or well above that.

Emil Billbäck
59:26 - 59:43

Yes, yes, that's about right. So, so, so somewhere between 40 and 50% of the procedures. Or if you want to, you can say rather 60 to 70% of the relevant procedures. Um, CERAMENT is then used.

Unknown
59:44 - 59:47

Okay. Great. Okay, thanks. That's all for me.

Emil Billbäck
59:49 - 59:49

Thank you, Oscar.

Matthias Watson
59:50 - 59:56

The next question comes from Matthias Watson from SEB. Please go ahead.

Unknown
59:58 - 60:35

Hi. Um, I was trying to go off the QB after. Is this running over? But now I'm here. Um. And then I have two short questions, maybe on spine and this data that you will collect. How will this, the percentage of the market suggest that with a press release and then also the spine. Would you say that the bone growth substitutes part of the market is growing faster in spine compared to extremities, over autograft and allograft. If you have any insights, we are interested. That's the only question.

Unknown
60:36 - 60:36

Okay.

Emil Billbäck
60:37 - 62:04

So we usually don't make a press release on pre-clinical studies. I think our standard is that when we have clinical studies that are of milestone character, then you will see us issue a press release. So, for example, the Solorio study will definitely be a press release on those results. On application data. I'm not so sure. I mean, the studies will at one stage be available so everyone can see the results, but I doubt that they will render attention enough to issue a release. I think rather, let's say, when we have our first patient case, when we have reached the first 100 cases, maybe on patients with spine, that's something we will be more happy to speak about. When it comes to growth rate in spine, spine has had formidable growth over the last 15 to 20 years. But right now, the growth rate is around 5%. And I do not have a split. On how the different segments autograft, allograft, or synthetics are growing. I have data over the last three years, but they are going a little bit in different directions. So I think right now we just conclude saying that the market is growing by about 5%.

Unknown
62:06 - 62:07

Thank you very much.

Emil Billbäck
62:08 - 62:10

Thank you, Mattias, and thanks for coming back.

Matthias Watson
62:16 - 62:36

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Emil Billbäck
62:38 - 63:02

Yeah okay. So thank you everyone for joining in on our presentation of the first quarter 2024 result. And although it's a busy morning for all of you, thank you also for your insightful questions. And if there are further topics that you would like to discuss, don't hesitate to contact me at BONESUPPORT. We'll be happy to support you to describe also our journey going forward. Thank you everyone and have a good continuation of the week. Bye bye.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…